Market research
CVM CEL-SCI Corporation
AMEX USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 25M
- P/E ratio
- Not available
- Analyst target
- 12.5
- Dividend yield
- Not available
- Beta
- 0.56
Profile
Company facts
- Exchange
- AMEX
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US1508377066
- Market cap
- 25M
- P/E ratio
- Not available
- Analyst target
- 12.5
- Dividend yield
- Not available
- Beta
- 0.56
About
About CEL-SCI Corporation
CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States. The company's lead immunotherapy is Multikine, which has completed Phase III clinical trials for the potential treatment of certain head and neck cancers. It is also developing Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer, as well as to potentially treat rheumatoid arthritis. In addition, the company's LEAP product candidates include CEL-2000; CEL-4000; and CEL-5000 that are in preclinical trials for potential rheumatoid arthritis therapeutic treatments. CEL-SCI Corporation has a strategic partnership with Saudi Arabian Pharma Company for Multikine in the treatment of head and neck cancer. The company was incorporated in 1983 and is headquartered in Vienna, Virginia.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the CVM discussion.
5 years, 4 months ago
CEL-SCI Corporation is currently in a long term downtrend where the price is trading 50.1% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
CEL-SCI Corporation's total revenue sank by 100.0% to $0 since the same quarter in the previous year.
Its net income has dropped by 45.0% to $-8M since the same quarter in the previous year.
Finally, its free cash flow fell by 65.5% to $-7M since the same quarter in the previous year.
Based on the above factors, CEL-SCI Corporation gets an overall score of 1/5.